Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.
about
Angiogenic factors in diagnosis, management, and research in preeclampsia.Maternofoetal complications and their association with proteinuria in a tertiary care hospital of a developing country.Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).New developments in the pathogenesis of preeclampsiaEarly prediction of preeclampsiaPlasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsiaPlGF in a clinical setting of pregnancies at risk of preeclampsia and/or intrauterine growth restriction.Function and control of human invasive trophoblast subtypes: Intrinsic vs. maternal control.First-trimester maternal factors and biomarker screening for preeclampsia.Pre-eclampsia part 2: prediction, prevention and management.Placental growth factor concentration in maternal circulation decreases after fetal death: lessons from a case series study.SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014.Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia.Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study.Dlx3 and GCM-1 functionally coordinate the regulation of placental growth factor in human trophoblast-derived cells.Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy.Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia.The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis.Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin.Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history
P2860
Q27692060-23714081-BAA7-4E5F-9ED0-CBEA309336CAQ33415327-0D1D0B4D-63ED-4438-B914-4092FD4740E6Q33579089-27162647-A043-4CCF-91F7-5CE7366A5B43Q33935675-3D0F2615-D94B-4640-A26F-3E1EFC0A9435Q34022344-0A508D22-AFB5-4B99-915C-4FD0A58A4747Q34119026-61CC345D-E680-47D8-AEAF-2C4CEEE2E5F4Q35538277-C6B3422B-FBB4-46EB-AB0B-0EEEB177114AQ35974116-FB9FA900-2025-4590-9641-781344A46992Q36857915-BCC454CC-933F-4E43-BC74-07C8E48E3472Q38207000-236AD4EF-9A15-40EF-AE69-3D20B672A35AQ38227251-84F289FE-AE48-42F4-BCD2-CCD3205E45E7Q38458497-CA6D6753-6CE1-43D3-AA40-C77CEC8294BEQ38594110-CAC46D7C-C430-416A-A6EB-BF834BE283CEQ38979806-10D3A702-D644-4404-B339-151F06C74E5FQ40323400-626CDF92-F173-4676-B5C3-B650BA232DC8Q40521260-4FCFC88C-E27B-4B96-8636-AC0EC69BA78FQ41033848-3EE7DD23-35A9-4490-9B3E-1C7BC2C344E3Q42503270-647CDBB6-8786-4129-8FF6-9FD0874F47A4Q47866706-DC0D11FB-04EA-4C95-9886-20BB2BF57CDCQ48287048-99CC2837-07D5-477F-BE04-738C8530396EQ49312791-5621BD75-E884-41A3-B1E2-1EDC00BD882FQ50017347-4C6C8BD1-C759-4F35-A462-980296318727Q50279605-8C3730FE-A164-4D61-A1DB-8000C41D753EQ51458803-DC988452-1C4C-4CD7-B106-ED6908E74825Q51516924-928F906D-DAA4-48FD-AF77-3D06F5910322Q57917834-C8A41A92-324A-487D-94CA-134F9613962D
P2860
Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Placental growth factor for th ...... trauterine growth restriction.
@ast
Placental growth factor for th ...... trauterine growth restriction.
@en
Placental growth factor for th ...... trauterine growth restriction.
@nl
type
label
Placental growth factor for th ...... trauterine growth restriction.
@ast
Placental growth factor for th ...... trauterine growth restriction.
@en
Placental growth factor for th ...... trauterine growth restriction.
@nl
prefLabel
Placental growth factor for th ...... trauterine growth restriction.
@ast
Placental growth factor for th ...... trauterine growth restriction.
@en
Placental growth factor for th ...... trauterine growth restriction.
@nl
P2093
P2860
P50
P1433
P1476
Placental growth factor for th ...... trauterine growth restriction.
@en
P2093
Jean Guibourdenche
Jeanne Sibiude
Marie-Danielle Dionne
Olivia Anselem
Vassilis Tsatsaris
P2860
P304
P356
10.1371/JOURNAL.PONE.0050208
P407
P577
2012-11-28T00:00:00Z